Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
New technology can rapidly disrupt existing biofilms that account for chronic diseases

New technology can rapidly disrupt existing biofilms that account for chronic diseases

Study sheds new light on protein movement

Study sheds new light on protein movement

Repurposed drug for acute lung injury in COVID-19

Repurposed drug for acute lung injury in COVID-19

Protein profile in serum reflects COVID-19 severity

Protein profile in serum reflects COVID-19 severity

Hormone involved in obesity could increase the risk for sepsis infection

Hormone involved in obesity could increase the risk for sepsis infection

New therapy provides relief in patients with chronic low back pain

New therapy provides relief in patients with chronic low back pain

NJIT researchers develop new efficient method for targeted protein analysis

NJIT researchers develop new efficient method for targeted protein analysis

An improved tetravalent antibody blocks SARS-CoV-2 infection

An improved tetravalent antibody blocks SARS-CoV-2 infection

Antibody cocktail with potential to treat COVID-19 identified

Antibody cocktail with potential to treat COVID-19 identified

Romosozumab offers considerable added benefit for postmenopausal women with osteoporosis

Romosozumab offers considerable added benefit for postmenopausal women with osteoporosis

Progression and severity of COVID-19 highly dependant on cytokine changes

Progression and severity of COVID-19 highly dependant on cytokine changes

Novel compound shows promise for ANCA-associated vasculitis

Novel compound shows promise for ANCA-associated vasculitis

AFFiRiS announces preclinical results of monoclonal antibody mAB C6-17 in Huntington's

AFFiRiS announces preclinical results of monoclonal antibody mAB C6-17 in Huntington's

Monoclonal antibody therapy achieves modest reduction in recurrence for patients with HER2-positive DCIS

Monoclonal antibody therapy achieves modest reduction in recurrence for patients with HER2-positive DCIS

Addition of monoclonal antibody to trimodality therapy offers no benefit in HER2 over expressing esophageal cancer

Addition of monoclonal antibody to trimodality therapy offers no benefit in HER2 over expressing esophageal cancer

Measuring the binding of SARS-CoV-2 antibodies to the COVID spike protein using SPR

Measuring the binding of SARS-CoV-2 antibodies to the COVID spike protein using SPR

The use of rheumatoid arthritis drug sarilumab in severe COVID-19 pneumonia

The use of rheumatoid arthritis drug sarilumab in severe COVID-19 pneumonia

Innovent Biologics and MD Anderson to develop sintilimab injection for rare cancers

Innovent Biologics and MD Anderson to develop sintilimab injection for rare cancers

Human immune repertoire may not commonly produce cross-neutralizing antibodies to coronaviruses

Human immune repertoire may not commonly produce cross-neutralizing antibodies to coronaviruses

Cross-neutralization of SARS and COVID-19 coronaviruses by a monoclonal antibody

Cross-neutralization of SARS and COVID-19 coronaviruses by a monoclonal antibody

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.